Literature DB >> 12150975

Neurotensin counteracts apoptosis in breast cancer cells.

Sonia Somaï1, Anne Gompel, William Rostène, Patricia Forgez.   

Abstract

Neurotensin (NT) is a neuropeptide interacting with specific G protein coupled receptors. In the periphery, NT is a hormone of the gastrointestinal tract. The high affinity neurotensin receptor (NT-1 receptor) is over-expressed in a numbers of cancers. Consequently NT growth effects, largely described in normal and adenocarcinomatous tissues, may be of a major importance in tumor proliferation. In this study we demonstrated an anti-apoptotic effect of NT agonist, in the mammary adenocarcinoma cells, MCF-7. Focusing on the cellular events involved, we found an increase in Bcl-2 protein and mRNA levels, resulting in Bcl-2 transcriptional activation, and dependent on MAP kinase pathway.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12150975     DOI: 10.1016/s0006-291x(02)00703-9

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  14 in total

1.  Expression of neurotensin receptor 1 in endometrial adenocarcinoma is correlated with histological grade and clinical outcome.

Authors:  Mikaël Agopiantz; Patricia Forgez; Jean-Matthieu Casse; Stéphanie Lacomme; Claire Charra-Brunaud; Isabelle Clerc-Urmès; Olivier Morel; Céline Bonnet; Jean-Louis Guéant; Jean-Michel Vignaud; Anne Gompel; Guillaume Gauchotte
Journal:  Virchows Arch       Date:  2017-08-24       Impact factor: 4.064

2.  The Internalization of Neurotensin by the Low-Affinity Neurotensin Receptors (NTSR2 and vNTSR2) Activates ERK 1/2 in Glioma Cells and Allows Neurotensin-Polyplex Transfection of tGAS1.

Authors:  Alberto E Ayala-Sarmiento; Daniel Martinez-Fong; José Segovia
Journal:  Cell Mol Neurobiol       Date:  2015-03-14       Impact factor: 5.046

3.  Nanoliposomal short-chain ceramide inhibits agonist-dependent translocation of neurotensin receptor 1 to structured membrane microdomains in breast cancer cells.

Authors:  Yasser Heakal; Mark Kester
Journal:  Mol Cancer Res       Date:  2009-05-12       Impact factor: 5.852

4.  A gene expression signature that defines breast cancer metastases.

Authors:  Rachel E Ellsworth; Jeff Seebach; Lori A Field; Caroline Heckman; Jennifer Kane; Jeffrey A Hooke; Brad Love; Craig D Shriver
Journal:  Clin Exp Metastasis       Date:  2008-12-27       Impact factor: 5.150

5.  Dimeric Prodrug Self-Delivery Nanoparticles with Enhanced Drug Loading and Bioreduction Responsiveness for Targeted Cancer Therapy.

Authors:  Xi He; Kaimin Cai; Yu Zhang; Yifei Lu; Qin Guo; Yujie Zhang; Lisha Liu; Chunhui Ruan; Qinjun Chen; Xinli Chen; Chao Li; Tao Sun; Jianjun Cheng; Chen Jiang
Journal:  ACS Appl Mater Interfaces       Date:  2018-11-09       Impact factor: 9.229

6.  Neurotensin and its high affinity receptor 1 as a potential pharmacological target in cancer therapy.

Authors:  Zherui Wu; Daniel Martinez-Fong; Jean Trédaniel; Patricia Forgez
Journal:  Front Endocrinol (Lausanne)       Date:  2013-01-17       Impact factor: 5.555

7.  The neurotensin receptor-1 pathway contributes to human ductal breast cancer progression.

Authors:  Sandra Dupouy; Véronique Viardot-Foucault; Marco Alifano; Frédérique Souazé; Geneviève Plu-Bureau; Marc Chaouat; Anne Lavaur; Danielle Hugol; Christian Gespach; Anne Gompel; Patricia Forgez
Journal:  PLoS One       Date:  2009-01-19       Impact factor: 3.240

8.  The anti-apoptotic role of neurotensin.

Authors:  Christelle Devader; Sophie Béraud-Dufour; Thierry Coppola; Jean Mazella
Journal:  Cells       Date:  2013-03-04       Impact factor: 6.600

9.  Suicide HSVtk gene delivery by neurotensin-polyplex nanoparticles via the bloodstream and GCV Treatment specifically inhibit the growth of human MDA-MB-231 triple negative breast cancer tumors xenografted in athymic mice.

Authors:  Rosa A Castillo-Rodríguez; Martha L Arango-Rodríguez; Lourdes Escobedo; Daniel Hernandez-Baltazar; Anne Gompel; Patricia Forgez; Daniel Martínez-Fong
Journal:  PLoS One       Date:  2014-05-13       Impact factor: 3.240

10.  Activation of EGFR, HER2 and HER3 by neurotensin/neurotensin receptor 1 renders breast tumors aggressive yet highly responsive to lapatinib and metformin in mice.

Authors:  Sandra Dupouy; Van Kien Doan; Zherui Wu; Najat Mourra; Jin Liu; Olivier De Wever; Frédérique Penault Llorca; Anne Cayre; Amal Kouchkar; Anne Gompel; Patricia Forgez
Journal:  Oncotarget       Date:  2014-09-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.